Brokerages Set Sunesis Pharmaceuticals (SNSS) Target Price at $4.12

Sunesis Pharmaceuticals (NASDAQ:SNSS) has been given an average rating of “Hold” by the seven brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.12.

A number of brokerages have recently commented on SNSS. Cantor Fitzgerald reiterated a “hold” rating and set a $4.00 price target on shares of Sunesis Pharmaceuticals in a report on Thursday, March 8th. ValuEngine lowered shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Finally, Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Tuesday, May 8th.

Shares of Sunesis Pharmaceuticals opened at $2.73 on Tuesday, Marketbeat reports. Sunesis Pharmaceuticals has a fifty-two week low of $2.66 and a fifty-two week high of $2.74.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. The company had revenue of $0.24 million during the quarter. sell-side analysts expect that Sunesis Pharmaceuticals will post -0.97 EPS for the current year.

Several large investors have recently modified their holdings of SNSS. Vatera Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the fourth quarter worth $673,000. Millennium Management LLC lifted its holdings in shares of Sunesis Pharmaceuticals by 594.4% during the first quarter. Millennium Management LLC now owns 106,599 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 91,248 shares during the period. Spark Investment Management LLC acquired a new position in shares of Sunesis Pharmaceuticals during the first quarter worth $204,000. Geode Capital Management LLC lifted its holdings in shares of Sunesis Pharmaceuticals by 105.2% during the fourth quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 64,343 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Sunesis Pharmaceuticals by 127.6% during the third quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 53,396 shares during the period. Institutional investors own 52.03% of the company’s stock.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Analyst Recommendations for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply